579 related articles for article (PubMed ID: 36425405)
1. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
2. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
4. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
5. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
Lavoie T; Appaneal HJ; LaPlante KL
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
[TBL] [Abstract][Full Text] [Related]
6. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
[TBL] [Abstract][Full Text] [Related]
7. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
[TBL] [Abstract][Full Text] [Related]
8. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
9. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
Pipek B; Valentová H; Fojtík P; Urban O
Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection.
Haifer C; Paramsothy S; Borody TJ; Clancy A; Leong RW; Kaakoush NO
mSystems; 2021 Feb; 6(1):. PubMed ID: 33531405
[TBL] [Abstract][Full Text] [Related]
11. Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent
Stallhofer J; Steube A; Katzer K; Stallmach A
Visc Med; 2024 Apr; 40(2):82-91. PubMed ID: 38584858
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.
McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR
Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.
Xu Q; Zhang S; Quan J; Wu Z; Gu S; Chen Y; Zheng B; Lv L; Li L
Appl Microbiol Biotechnol; 2022 Oct; 106(19-20):6689-6700. PubMed ID: 36085529
[TBL] [Abstract][Full Text] [Related]
14. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
[TBL] [Abstract][Full Text] [Related]
15. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent
Khanna S; Sims M; Louie TJ; Fischer M; LaPlante K; Allegretti J; Hasson BR; Fonte AT; McChalicher C; Ege DS; Bryant JA; Straub TJ; Ford CB; Henn MR; Wang EEL; von Moltke L; Wilcox MH
Antibiotics (Basel); 2022 Sep; 11(9):. PubMed ID: 36140013
[TBL] [Abstract][Full Text] [Related]
16. Functional profile of host microbiome indicates
Nzabarushimana E; Tang H
Gut Microbes; 2022; 14(1):2135963. PubMed ID: 36289064
[TBL] [Abstract][Full Text] [Related]
17. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
[TBL] [Abstract][Full Text] [Related]
18. Expert opinion on fecal microbiota transplantation for the treatment of
Kumar V; Fischer M
Expert Opin Biol Ther; 2020 Jan; 20(1):73-81. PubMed ID: 31690143
[No Abstract] [Full Text] [Related]
19. Fecal microbiota transplantation for treatment of patients with recurrent
Voth E; Khanna S
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
[TBL] [Abstract][Full Text] [Related]
20. Clostridioides
Gawey BJ; Khanna S
Gastroenterol Hepatol (N Y); 2023 Jun; 19(6):319-328. PubMed ID: 37706187
[No Abstract] [Full Text] [Related]
[Next] [New Search]
